Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting »
Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of interim Phase 2 data with 7 months average follow up evaluating the safety of suprachoroidal (SC) administration of AU-011, the Company’s lead product candidate for the first-line treatment of primary choroidal melanoma, as a part of the American Society of Retina Specialists (ASRS) 2021 Annual Meeting.
Aura Biosciences Expands Executive Leadership Team and Board of Directors »
Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the appointment of Chris Primiano, J.D., as Chief Business Officer and the appointment of Antony Mattessich to its Board of Directors.
Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board »
Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the formation of a new, urologic oncology focused Scientific Advisory Board (SAB).
Aura Biosciences Appoints Sapna Srivastava, Ph.D., to its Board of Directors »
Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the appointment of Sapna Srivastava, Ph.D., to its Board of Directors.
Aura Biosciences Presents New Preclinical AU-011 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting »
Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of supportive preclinical data in multiple tumor models of choroidal metastases and in choroidal melanoma using suprachoroidal administration
Aura Biosciences Announces Publication of Data in Cancer Immunology Research Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform »
Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the online publication of data in the peer-reviewed medical journal Cancer Immunology Research, a journal of the American Association for Cancer Research, that supports the broad application of the Company’s proprietary VDC technology platform for treating cancer
Aura Biosciences Expands Executive Leadership Team with the Appointment of Mark De Rosch, Ph.D., as Chief Operating Officer »
Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the appointment of Mark De Rosch, Ph.D. as Chief Operating Officer. In his role, he will be responsible for leading Aura’s global operations and regulatory strategy.
Aura Biosciences Announces Oversubscribed $80 Million Financing »
Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the closing of an oversubscribed $80 million financing. The financing was led by Matrix Capital Management and Surveyor Capital (a Citadel company) with participation from new investors, including Rock Springs Capital, Adage Capital Management LP and Velosity Capital.
Aura Biosciences Appoints David Johnson to Its Board of Directors »
Aura Biosciences, a clinical-stage oncology company developing a novel class of drug conjugate therapies for multiple oncology indications, today announced the appointment of David Johnson to its Board of Directors. Mr. Johnson is a biopharmaceutical business leader with more than 25 years of experience in drug development and currently serves as Chief Executive Officer at VelosBio, a clinical-stage oncology company developing novel antibody-drug-conjugates and bispecific antibodies.
Aura Biosciences Announces AU-011 Data from Phase 1b/2 Clinical Trial Selected for Late Breaking Presentation at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting »
Aura Biosciences today announced that an abstract has been selected as a late breaking presentation as part of the Retina Subspecialty Day at the upcoming American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting, taking place November 14-17, 2020. The abstract details results from the ongoing intravitreal administration Phase 1b/2 clinical study and suprachoroidal administration Phase 2 clinical study evaluating AU-011 in patients with choroidal melanoma.
Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma »
Aura Biosciences today announced the virtual presentation of updated clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the first line treatment of primary choroidal melanoma, as part of the Association for Research in Vision and Ophthalmology (ARVO) 2020 Annual Meeting.
Aura Biosciences Presents Updated AU-011 Clinical Data at ARVO 2020 »
Aura Biosciences today announced the virtual presentation of updated clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the first line treatment of primary choroidal melanoma, as part of the Association for Research in Vision and Ophthalmology (ARVO) 2020 Annual Meeting.
Aura Biosciences’ Scientific Founder Dr. John Schiller Elected to the National Academy of Sciences »
Congratulations to Aura Biosciences’ Scientific Founder, Deputy Chief of the Laboratory of Cellular Oncology at the National Cancer Institute and NIH Distinguished Investigator Dr. John Schiller on his election to the National Academy of Sciences for his distinguished work pioneering viral-like particle drug discovery.
Aura Biosciences to Present at the Cowen 40th Annual Health Care Conference »
Aura Biosciences today announced that Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura, will present a company overview at the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020, at 9:30 a.m. Eastern Time in Boston, MA.
Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting »
Aura Biosciences today announced the presentation of updated clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the first line treatment of primary choroidal melanoma, at the 43rd Annual Macula Society Meeting, which took place February 19-22, 2020 in San Diego, CA.
Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors »
Aura Biosciences today announced the appointment of George Golumbeski, Ph.D., as Chairman of its Board of Directors. Dr. Golumbeski is a biopharmaceutical business leader with over 25 years of experience in the biotechnology industry.
Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual Meeting »
Aura Biosciences today announced the presentation of updated clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the first line treatment of primary choroidal melanoma, at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting, being held October 12-15, 2019 in San Francisco, CA.
Aura Biosciences Announces Clinical Data Presentations at the Upcoming American Academy of Ophthalmology 2019 Annual Meeting »
Aura Biosciences today announced multiple data presentations at the upcoming American Academy of Ophthalmology (AAO) 2019 Annual Meeting being held October 12-15, 2019 in San Francisco, CA. Aura’s lead clinical asset, AU-011, will also be highlighted in presentations at related medical meetings taking place in San Francisco around AAO 2019, including the Ophthalmology Innovation Summit taking place October 10, 2019, and the American Association of Ophthalmic Oncologists and Pathologists (AAOOP) 2019 Annual Meeting taking place October 13, 2019.
Aura Biosciences Announces Participation at Upcoming Investor Conferences »
Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that members of Aura’s executive team will participate in the following upcoming investor conferences: Canaccord Genuity’s 39th Annual Growth Conference on August 8, 2019 in Boston, MA and will present at 2:00 p.m. Eastern Time BTIG Biotechnology Conference on August 12, 2019 in New York, NY
Aura Biosciences to Present Long-Term Clinical Data for AU-011 at the 37th Annual Scientific Meeting of the American Society of Retina Specialists »
Aura Biosciences announced that two-year clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the 37th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held July 26- 30, 2019 in Chicago, Illinois.
Aura Biosciences to Present Interim Phase 1b/2 Clinical Data for AU-011 at the European Society of Ophthalmology 2019 Congress »
Aura Biosciences announced that interim clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the European Society of Ophthalmology 2019 Congress being held June 13-16, 2019, in Nice, France.
Aura Biosciences to Present at the Jefferies 2019 Global Healthcare Conference »
Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura Biosciences, will present a company overview at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019, at 2:00 p.m. Eastern Time in New York, NY.
Aura Biosciences to Present Two Year Phase 1b/2 Clinical Data for AU-011 at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting »
Aura Biosciences announced that two year clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the primary treatment of primary choroidal melanoma, will be highlighted in a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting being held April 28-May 2, 2019, in Vancouver, British Columbia.
Aura Biosciences Completes $40 Million Series D Financing »
Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with current investors also participating.
Aura Biosciences to Present Interim Phase 1b/2 Clinical Data for AU-011 at the International Society of Ocular Oncology 2019 Annual Meeting »
Aura Biosciences today announced that interim clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the primary treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the International Society of Ocular Oncology (ISOO) 2019 Annual Meeting being held March 22-26, 2019, in Los Angeles.
Aura Biosciences to Present at Upcoming Investor Conferences »
Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that management will present a company overview at the following investor conferences: Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, at 10:00 a.m. Eastern Time in Boston, MA Oppenheimer's 29th Annual Healthcare Conference on Tuesday, March 19, 2019, at 9:10 a.m. Eastern Time in New York, NY
Aura Biosciences Announces Successful Outcome of End of Phase 2 Meeting with FDA for AU-011 for the Treatment of Patients with Choroidal Melanoma »
The company has received written confirmation from the U.S. Food and Drug Administration (FDA) regarding agreement on the design of its Phase 3 registration trials designed to evaluate light-activated AU-011 for the treatment of patients with choroidal melanoma. This written confirmation is the result of successful outcome of an “End of Phase 2” meeting with the FDA.
Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the American Academy of Ophthalmology 2018 Annual Meeting »
The data presented at the meeting show that multiple administrations of light-activated AU-011 are well-tolerated with no related serious adverse events, severe adverse events or dose-limiting toxicities observed.
Aura Biosciences to Present Phase 1b/2 Clinical Data for AU-011 at the American Academy of Ophthalmology 2018 Annual Meeting »
Phase 1b/2 clinical data for AU-011, the Company’s lead product candidate for the primary treatment of choroidal melanoma, will be presented in two oral presentations at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting being held October 27-30, 2018, at McCormick Place in Chicago.
Aura Biosciences Boosts Finance Team with Two Key Appointments, Preparing to Move Into Late-Stage Clinical Development in Ocular Melanoma »
Julie Feder has joined Aura as Chief Financial Officer, and Kylie Reynolds has joined as Vice President of Finance.
Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting »
Interim data show that AU-011 has been generally well-tolerated in the multiple ascending dose cohort of the ongoing clinical trial.
Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma »
Interim data presented today show that AU-011 has been generally well-tolerated, and early efficacy results are very promising.
Aura Biosciences Completes $30 Million Series C Financing »
Aura announced that it has closed $30 million in Series C financing, which will support ongoing clinical development, enabling buildout of company infrastructure and GMP manufacturing
Aura Biosciences Announces Publication of Preclinical Data Supporting AU-011’s Potent and Selective Anti-cancer Activity in Ocular Melanoma Tumors »
Aura announced that researchers at Massachusetts Eye and Ear (MEE), Emory University and the National Cancer Institute (NCI) have generated preclinical data that demonstrate the ability of light-activated AU-011 to target and selectively destroy ocular melanoma tumors.
Aura Biosciences Strengthens Leadership Team with Addition of Cadmus Rich, M.D., as Chief Medical Officer »
Aura announced that Cadmus Rich, M.D., has joined the company’s leadership team as Chief Medical Officer.
Aura Biosciences Announces Interim Phase 1b/2 Data on Light-Activated AU-011 for Primary Ocular Melanoma »
Interim Phase 1b/2 data on AU-011 presented by Carol Shields, M.D., at AAO 2017 show safety and preliminary efficacy at three months post-treatment.
New Clinical Data from Aura Biosciences to be Featured in Presentation at the American Academy of Ophthalmology 2017 Annual Meeting »
Carol Shields, M.D., of the Wills Eye Hospital in Philadelphia, will present data from Aura's Phase 1b clinical safety study of AU-011 at AAO 2017.
Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma »
Aura has enrolled and dosed at Wills Eye Hospital the first patient in its Phase 1b clinical trial of AU-011. The company also has received FDA fast track designation for AU-011 for the treatment of primary ocular melanoma.
Aura Biosciences Receives FDA Clearance of Investigational New Drug Application for Light-activated AU-011 for the Treatment of Ocular Melanoma »
Aura has received IND clearance from the U.S. FDA for its lead program, light-activated AU-011 in ocular melanoma (OM). This active IND enables Aura to begin initial clinical testing of AU-011, a unique targeted therapy that could transform the primary treatment of patients with OM.
Aura Biosciences Secures $8 Million in Additional Funding and Augments Board of Directors and Clinical Advisory Board »
Aura secured an additional $8 million round of funding to advance AU-011 to the clinic. The company also announced the addition of Henri Termeer, former CEO of Genzyme and major Aura investor, to its Board of Directors, and welcomed key new Clinical Advisory Board (CAB) members, all distinguished ocular oncologists.
Aura Biosciences to Present at the Ophthalmology Innovation Summit 2016 »
Aura's CEO, Eli de los Pinos, will present a company overview at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2016 Annual Meeting (OIS@AAO) in Chicago on Thursday, October 13, 2016, at 11 a.m. EST.
Aura Biosciences to Participate in the Boston Miles for Melanoma Run/Walk »
Aura Biosciences announced today that it will participate in the Boston Miles for Melanoma 5K Run/Walk, in support of the Melanoma Research Foundation’s (MRF) research, advocacy and education efforts.
Aura Biosciences to Present at the 15th Annual Needham Healthcare Conference »
Elisabet de los Pinos, Aura's founder and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference in New York, N.Y. The presentation will take place on Tuesday, April 12, 2016, at 2:40 p.m. EDT.
Aura Biosciences Forms Clinical Advisory Board in Ocular Oncology and Strengthens Clinical Team to Prepare for Clinical Development of Lead Program in Ocular Melanoma »
Click here to learn more about the newest additions to the Aura team.
Aura Biosciences Announces Publication Describing Selective Binding of Viral-like Particles to Cancer Cells »
Aura announced today the publication of a new paper demonstrating how its synthetic Viral-like Particles (VLP) modeled on the human papillomavirus (HPV) are able to bind uniquely to cancer cells while leaving healthy surrounding tissue unharmed.
FDA Grants Orphan Drug Designation to Aura Biosciences’ Novel Treatment for Uveal Melanoma »
Aura has been granted Orphan Disease Designation by the FDA for its drug AU-011 for the treatment of Uveal Melanoma.
Aura Biosciences Closes $21M Series B Financing »
Aura Biosciences, a biotech company developing highly tumor-targeted breakthrough therapies for rare cancers, has secured a $21M Series B round of funding.